PlumX Metrics
Embed PlumX Metrics

Low-grade primary splenic CD10-positive small B-cell lymphoma/follicular lymphoma

Current Oncology, ISSN: 1718-7729, Vol: 28, Issue: 6, Page: 4821-4831
2021
  • 6
    Citations
  • 512
    Usage
  • 11
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent Blog

Current Oncology, Vol. 28, Pages 4821-4831: Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma

Current Oncology, Vol. 28, Pages 4821-4831: Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma Current Oncology doi: 10.3390/curroncol28060407 Authors: Rami Abdulbaki Parastou Tizro Victor E.

Review Description

Primary splenic lymphoma (PSL) is a rare malignancy representing about 1% of all lymphoproliferative disorders, when using a strict definition that allows only involvement of spleen and hilar lymph nodes. In contrast, secondary low-grade B-cell lymphomas in the spleen, such as follicular lymphomas (FL), lymphoplasmacytic lymphoma and chronic lymphocytic leukemia/ small lymphocytic lymphoma, particularly as part of advanced stage disease, are more common. Indolent B cell lymphomas expressing CD10 almost always represent FL, which in its primary splenic form is the focus of this review. Primary splenic follicular lymphoma (PSFL) is exceedingly infrequent. This type of lymphoproliferative disorder is understudied and, in most cases, clinically characterized by splenomegaly or cytopenias related to hypersplenism. The diagnosis requires correlation of histopathology of spleen, blood and/or bone marrow with the correct immunopheno-type (determined by flow cytometry and/or immunohistochemistry) and if necessary, additional molecular profiling. Management of this incurable disease is evolving, and splenectomy remains the mainstream treatment for stage I PSFL.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know